Comorbid patient with chronic pain syndrome

E.V. Ekusheva

Federal Clinical Research Centre of the Federal Medical-Biological Agency, Moscow

Chronic pain syndrome is observed in more than 20% of the world population. The most common are chronic back pain, joint pain, headache and neuropathic pain. Currently, the most effective is considered to be a comprehensive multidisciplinary approach to the patients’ treatment with chronic pain, including pharmacological therapy with drugs of proven efficacy and various non-drug exposure methods. The issues of not only reducing the chronic pain syndrome intensity but also improving the functional activity and life quality, including patients with chronic neuropathic pain and concomitant comorbidity, remain relevant. In the treatment of this patient category, an adequate and long-lasting result is not always achieved, which necessitates the search for more effective and safe means for the pain syndrome treatment. The use of physiologically active pyrimidine nu cleotides acting on peripheral nerves and promoting their physiological regeneration in pathological conditions, along with neutropic components (choline and vitamins from group B), is one of the promising areas. The proven clinical efficacy and safety of the combined biologically active adjuvants in-take make it possible to successfully apply Neurospan and Neurospan Forte (the complex is characterized by a triple content of uridine monophosphate, the presence of choline and neutrotropic vitamins in the composition) in the complex therapy of patients with chronic pain syndrome and concomitant comorbidity.

Keywords: pain syndrome, chronic pain, neuropathic pain, pyrimidine nucleotides, uridine monophosphate, uridine, B vitamins, Neurospan Forte.

For citation: Ekusheva E.V. Comorbid patient with chronic pain syndrome. RMJ. 2019;9:44–48.